期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 174, 期 5, 页码 767-775出版社
WILEY
DOI: 10.1111/bjh.14132
关键词
Chronic lymphocytic leukaemia; prolymphocytes; prognostic markers; molecular markers; morphology
类别
资金
- Bloodwise [11052, 12050]
- Arbib Charitable Fund
- Kay Kendall Leukaemia Fund [KKL584]
- Wessex Medical Research
- Cancer Research UK [C328/A2738, C328/A2737]
- Schering Health Care (UK)
- Schering AG (Germany)
Historically, an increase in the percentage and number of circulating prolymphocytes in chronic lymphocytic leukaemia (CLL) has been associated with strong expression of surface immunoglobulin, trisomy 12 and a poor outcome. This study re-examines the biological and clinical significance of increased peripheral blood prolymphocytes in 508 patients at entry into the randomized UK Leukaemia Research Fund CLL4 trial. It also investigates the associations between increased prolymphocytes and a comprehensive array of biomarkers. 270 patients (53%) had <5% prolymphocytes, 167 (33%) had 5-9%, 60 (12%) had 10-14% and 11 (2%) had 15% prolymphocytes. We show that a higher proportion of prolymphocytes (10%) was independently associated with NOTCH1 mutations (P=0006), absence of 13q deletion (P=0001), high CD38 expression (P=002) and unmutated IGHV genes (P=001). Deaths due to Richter syndrome were significantly more common amongst patients who had 10% vs <10% prolymphocytes (13% vs 2%) respectively (P<00001). 10% prolymphocytes was also associated with a shorter progression-free survival (Hazard ratio [HR] 150 [95% confidence interval [CI]: 116-193], P=0002) and overall survival (HR 199 [95% CI: 153-259], P<00001). Our data support the routine examination of blood films in CLL and suggest that a finding of an increased proportion of prolymphocytes may be a trigger for further evaluation of clinical and laboratory features of progressive disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据